AveXis to Report Third Quarter 2017 Financial and Operating Results
November 02 2017 - 8:00AM
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company
developing treatments for patients suffering from rare and
life-threatening neurological genetic diseases, will report
financial and operating results for the third quarter ended
September 30, 2017, on Thursday, November 9, 2017, after the close
of U.S.-based financial markets. AveXis management will host a
conference call and live webcast at 4:30 p.m. Eastern Standard
Time.
Analysts and investors can participate in the conference call by
dialing (844) 889-6863 for domestic callers and (661) 378-9762 for
international callers, using the conference ID 3899689. The webcast
can be accessed live on the Events and Presentations page in the
Investors and Media section of the AveXis website,
www.AveXis.com. The webcast will be archived on the company’s
website until its next quarterly earnings call, and will be
available for telephonic replay for 14 days following the call by
dialing (855) 859-2056 (Domestic) or (404) 537-3406
(International), conference ID 3899689.
About SMA SMA is a severe neuromuscular disease
characterized by the loss of motor neurons leading to progressive
muscle weakness and paralysis. SMA is caused by a genetic defect in
the SMN1 gene that codes SMN, a protein necessary for survival of
motor neurons. The incidence of SMA is approximately one in 10,000
live births. SMA is the leading genetic cause of infant
mortality.
The most severe form of SMA is Type 1, a lethal genetic disorder
characterized by motor neuron loss and associated muscle
deterioration, which results in mortality or the need for permanent
ventilation support before the age of two for greater than 90
percent of patients.
About AVXS-101AVXS-101 is a proprietary gene
therapy candidate of a one-time treatment for SMA Type 1, designed
to address the monogenic root cause of SMA and prevent further
muscle degeneration by addressing the defective and/or loss of the
primary SMN gene. AVXS-101 also targets motor neurons, providing
rapid onset of effect and crossing the blood brain barrier to allow
effective targeting of both central and systemic features.
About AveXis, Inc.AveXis is a clinical-stage
gene therapy company developing treatments for patients suffering
from rare and life-threatening neurological genetic diseases. The
company’s initial proprietary gene therapy candidate, AVXS-101, is
in the pivotal phase of study for the treatment of SMA Type 1. The
company also intends to expand the study of gene therapy into SMA
Type 2 and two additional rare neurological monogenic disorders:
Rett syndrome (RTT) and a genetic form of amyotrophic lateral
sclerosis (ALS) caused by mutations in the superoxide dismutase 1
(SOD1) gene.
For additional information, please visit www.avexis.com.
Media Inquiries:Lauren BarbieroW2O
Group646-564-2156lbarbiero@w2ogroup.com
Investor Inquiries: Jim GoffAveXis,
Inc.650-862-4134jgoff@avexis.com
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jul 2023 to Jul 2024